Clinical Trials
30 trialsStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
KEYVIBE-005
Merck Sharp & Dohme LLC
CRS/HIPEC
Mercy Medical Center
OvIP1
University Hospital, Ghent
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Ruhr University of Bochum
PemCiGem
Cedars-Sinai Medical Center
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Zhongshan Hospital Xiamen University
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
University of Maryland, Baltimore
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
National Institutes of Health Clinical Center (CC)
PGA
Western Regional Medical Center
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
University of Oklahoma
HIPEC
Columbia University
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Shenzhen SiBiono GeneTech Co.,Ltd
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
Children's Oncology Group
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
GOG Foundation
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
GOG Foundation
S9912 Combination Chemo in Stage III Ovarian Cancer,
SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NYU Langone Health
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
NYU Langone Health
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Scripps Health
Tax-Over
Sanofi
Gemcitabine in Ovarian Cancer
Eli Lilly and Company